City Therapeutics (CTY) closed at $18.98 on November 12, 2026, up 11.6% from the previous close, on volume of 212,010 shares (30-day average 333,008).
Data as of November 12, 2026.
City Therapeutics Doses First Participant in CITY-RBP4 Phase 1 Trial
TipRanks (Tue, 10-Nov 7:34 AM ET)
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
TipRanks (Tue, 10-Nov 2:45 AM ET)
TipRanks (Tue, 10-Nov 2:45 AM ET)
Globe Newswire (Wed, 4-Nov 9:01 AM ET)
City Therapeutics to Present at Upcoming November Investor Conferences
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
City Therapeutics trades on the NASDAQ stock market under the symbol CTY.
As of November 12, 2026, CTY stock price climbed to $18.98 with 212,010 million shares trading.
CTY has a market cap of $955.31 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that CTY belongs to (by Net Assets): HRTS.
CTY support price is $15.80 and resistance is $18.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTY shares will trade within this expected range on the day.
